Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C.
Lynce F, et al. Among authors: denduluri n.
Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x.
Nat Commun. 2024.
PMID: 38538574
Free PMC article.
Clinical Trial.